TNIP1抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Mouse muscle tissue, Hela cells, Primary antibody: P12312(TNIP1 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P12312(TNIP1 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

TNIP1 (TNFAIP3-interacting protein 1), also known as ABIN1 (A20-binding inhibitor of NF-κB 1), is a ubiquitin-binding protein involved in regulating inflammatory signaling pathways, particularly the NF-κB and mitogen-activated protein kinase (MAPK) pathways. It interacts with TNFAIP3 (A20), a critical negative regulator of inflammation, to suppress NF-κB activation and maintain immune homeostasis. TNIP1 plays a role in preventing excessive immune responses and has been implicated in autoimmune diseases, such as psoriasis, systemic lupus erythematosus (SLE), and rheumatoid arthritis, as well as cancers and metabolic disorders.

TNIP1 antibodies are essential tools for studying the protein's expression, localization, and function in both physiological and pathological contexts. These antibodies are commonly used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and co-immunoprecipitation (Co-IP) to investigate TNIP1's interactions with signaling molecules, its post-translational modifications, and its regulatory effects on inflammatory pathways. Researchers also utilize TNIP1 antibodies to explore its role in disease mechanisms, particularly in tissues where dysregulated NF-κB signaling contributes to pathogenesis. Validated antibodies are critical for ensuring specificity, given the structural similarities among ABIN protein family members. Recent studies have highlighted TNIP1's potential as a therapeutic target or biomarker, driving demand for reliable antibodies to support translational research.